| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Oriordan Anne serves as a Director at JAZZ. Across recent SEC filings that breaks down to 0 buys and 4 sells. Those positions are worth an estimated $1.8M at current prices.
Historically, Oriordan Anne's trades have earned a middling insider score of 61/100 across 3 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +13.0%.
The biggest single holding is JAZZ (~$1.8M) as Director. The recent filings there lean toward selling, a net 2,796 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2023 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 1,241 | $138.16 | $171,454.08 | -9.0% | -12.9% | -20.2% | |
| Aug 8, 2022 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 1,089 | $152.32 | $165,876.92 | -9.2% | -5.7% | -14.2% | |
| May 9, 2022 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 466 | $148.95 | $69,410.85 | -4.8% | +8.6% | -4.5% |